An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: Based on the results of the SOTI and TROPOS trials

Osteoporosis International

Volumn 17, Issue 12, 2006, Pages 1781-1793

  Borgstrom F ^a,b   Jonsson B ^c   Strom O ^a   Kanis, J A ^d  

^a STOCKHOLM HEALTH ECONOMICS   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Cost effectiveness; Osteoporosis; Postmenopausal; Strontium ranelate

Indexed keywords

STRONTIUM RANELATE;

ARTICLE; BONE DENSITY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; LIFE EXPECTANCY; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; SWEDEN; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS, PHASE III; CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; FEMALE; FRACTURES, BONE; HEALTH CARE COSTS; HUMANS; MARKOV CHAINS; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; SWEDEN; THIOPHENES; TREATMENT OUTCOME;

EID: 33750204879     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-006-0193-z     Document Type: Article

References (57)

1. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350(5):459-468
2. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90(5):2816-2822
3. Johnell O, Jonsson B, Jonsson L, Black D (2003) Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21(5):305-314
4. Borgstrom F, Zethraeus N (2003) Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective. Lakartidningen 100(1-2):36-40
5. Borgstrom F, Johnell O, Jonsson B, Zethraeus N, Sen SS (2004) Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone 34(6):1064-1071
6. Jonsson L, Borgstrom F, Zethraeus N (2003) Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the Fracture Intervention Trial. Ugeskr Laeger 165(43):4112-4116
7. Kanis JA, Borgstrom F, Johnell O, Jonsson B (2004) Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 15(11):862-871
8. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CC Jr, Lindsay R (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8(5):468-489
9. Seeman E, Vellas B, Meunier P, Roux C, Adami S, Aquino J, Semler J, Graham J, Sorensen O (2005) Vertebral and nonvertebral antifracture efficacy of strontium ranelate in very elderly women with osteoporosis. Osteoporos Int 16(Suppl 3):OC21:S6
10. European Medicines Agency. Summary of Product Characteristics (SPC). Available online at http://www.emea.eu.int/humandocs/PDFs/EPAR/protelos/H-560- PI-en.pdf
11. Reginster JY, Meunier PJ (2003) Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies. Osteoporos Int 14(Suppl 3):S56-S65
12. Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C (2002) Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos Int 13(12):925-931
13. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors-Nielsen S, De Vernejoul MC, Roces A, Reginster JY (2002) Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 87(5):2060-2066
14. Jonsson B (1998) Targeting high-risk populations. Osteoporos Int 8(Suppl 1):S13-S16
15. Jonsson B, Christiansen C, Johnell O, Hedbrandt J, Karlsson G (1996) Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol Suppl 103:30-38
16. Borgstrom F, Johnell O, Kanis JA, Oden A, Sykes D, Jonsson B (2004) Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics 22(17):1153-1165
17. Kanis JA, Borgstrom F, Johnell O, Oden A, Sykes D, Jonsson B (2005) Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int 16(1):15-25
18. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, de Laet C, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int 11(8):669-674
19. Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12(5):417-427
20. Melton LJ 3rd, Crowson CS, O'Fallon WM (1999) Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 9(1):29-37
21. Kanis JA, Johnell O, Oden A, Jonsson B, Dawson A, Dere W (2000) Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int 11 (2):120-127
22. de Laet CE, van Hout BA, Burger H, Hofman A, Pols HA (1997) Bone density and risk of hip fracture in men and women: cross sectional analysis. Br Med J 315(7102):221-225
23. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 312(7041):1254-1259
24. Kanis JA, Johnell O, de Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35(2):375-382
25. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15(4):721-739
26. Statistics Sweden. Sweden's Statistical Databases (SSD). Available online at http://www.scb.se/eng/databaser/ssd.asp
27. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures. Osteoporos Int 11 (7):556-561
28. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353(9156):878-882
29. Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ 3rd (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137(9):1001-1005
30. Jalava T, Sarna S, Pylkkanen L, Mawer B, Kanis JA, Selby P, Davies M, Adams J, Francis RM, Robinson J, McCloskey E (2003) Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res 18(7):1254-1260
31. Kanis JA, Oden A, Johnell O, de Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15(2):108-112
32. Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis JA (1998) Lifetime risk of hip fractures is underestimated. Osteoporos Int 8(6):599-603
33. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, de Laet C, Jonsson B (2004) Mortality after osteoporotic fractures. Osteoporos Int 15(1):38-42
34. Poor G, Atkinson EJ, O'Fallon WM, Melton LJ 3rd (1995) Determinants of reduced survival following hip fractures in men. Clin Orthop Oct(319):260-265
35. Kanis J, Johnell O, Oden A, de Laet C, Jonsson B, Oglesby A (2002) Excess mortality after vertebral fracture. WHO Collaborating Centre for Metabolic Bone Diseases, Sheffield, UK
36. Parker MJ, Anand JK (1991) What is the true mortality of hip fractures? Public Health 105(6):443-446
37. Kanis JA, Oden A, Johnell O, de Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32(5):468-473
38. Läkemedelsförmånsnämndens allmänna råd (2003) Stockholm
39. Zethraeus N, Stromberg L, Jonsson B, Svensson O, Ohlen G (1997) The cost of a hip fracture. Estimates for 1,709 patients in Sweden. Acta Orthop Scand 68(1):13-17
40. Zethraeus N, Borgström F, Johnell O, Kanis J, Jönsson B (2002) Costs and quality of life associated with osteoporosis related fractures - results from a Swedish survey. Working Paper Series in Economics and Finance, no 512, Stockholm School of Economics, Stockholm, Sweden
41. Stockholms stads budgetavräkning 2003. Available online at http://www.stockholm.se/files/71600-71699/file_71645.pdf
42. de Laet CE, vanHout BA, Burger H, WeelAE, Hofman A, Pols HA (1999) Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study. Osteoporos Int 10(1):66-72
43. Meltzer D (1997) Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 16(1):33-64
44. Ekman M, Zethraeus N, Dahlstrom U, Hoglund C (2002) Cost-effectiveness of bisoprolol in chronic heart failure. Lakartidningen 99(7):646-650
45. FASS för förskrivare. Home page at http://www.fass.se
46. Priser för södra sjukvårdsregionen- Vårdtjänster per klinik (2003) Universitetssjukhuset i Lund
47. Burstrom K, Johannesson M, Diderichsen F (2001) Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 10(7):621-635
48. Kind P, Dolan P, Gudex C, Williams A (1998) Variations in population health status: results from a United Kingdom national questionnaire survey. Br Med J 316(7133):736-741
49. Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, de Laet C, Jonsson B (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15(1):20-26
50. Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C, Kanis J (2000) Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 15(7):1384-1392
51. Brazier JE, Green C, Kanis JA (2002) A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 13(10):768-776
52. Tidermark J, Zethraeus N, Svensson O, Tornkvist H, Ponzer S (2002) Quality of life related to fracture displacement among elderly patients with femoral neck fractures treated with internal fixation. J Orthop Trauma 16(1):34-38
53. (2002) Översyn av samhällsekonomiska metoder och kalkylvården på transportområdet - ASEK review of cost benefit calculation. Methods and valuations in the transport sector. SIKA Rapport 4
54. Persson U, Hjelmgren J (2003) Health services need knowledge of how the public values health. Lakartidningen 100(43):3436-3437
55. Borgstrom F, Johnell O, Kanis JA, Oden A, Sykes D, Jönsson B (2004) Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden - an economic evaluation based on the MORE study. Pharmacoeconomics 22(17):1153-1165
56. (2003) PROTELOS - prevention and treatment of postmenopausal osteoporosis. Clinical Investigators' brochure no 7
57. Ross PD, Genant HK, Davis JW, Miller PD, Wasnich RD (1993) Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women. Osteoporos Int 3(3):120-126